United Therapeutics Corporation
UTHR
$535.65
-$0.48-0.09%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.38% | 6.76% | 11.71% | 17.22% | 19.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.38% | 6.76% | 11.71% | 17.22% | 19.72% |
| Cost of Revenue | 36.23% | 21.42% | 12.60% | 26.89% | 6.90% |
| Gross Profit | 4.06% | 4.93% | 11.60% | 16.05% | 21.39% |
| SG&A Expenses | 16.74% | 17.98% | 19.65% | 17.80% | 25.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.23% | 20.40% | 9.90% | 28.06% | 5.80% |
| Operating Income | -1.77% | -4.63% | 13.94% | 7.44% | 38.55% |
| Income Before Tax | 11.98% | 12.71% | 14.95% | 6.25% | 34.22% |
| Income Tax Expenses | -16.28% | 24.91% | 28.11% | 10.11% | 21.58% |
| Earnings from Continuing Operations | 20.91% | 9.58% | 11.29% | 5.09% | 38.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.91% | 9.58% | 11.29% | 5.09% | 38.78% |
| EBIT | -1.77% | -4.63% | 13.94% | 7.44% | 38.55% |
| EBITDA | -0.86% | -3.77% | 13.88% | 8.43% | 38.81% |
| EPS Basic | 24.82% | 11.58% | 9.56% | 10.00% | 45.93% |
| Normalized Basic EPS | 2.13% | -2.15% | 14.40% | 14.21% | 57.13% |
| EPS Diluted | 24.54% | 12.05% | 9.57% | 7.46% | 42.09% |
| Normalized Diluted EPS | 1.86% | -1.67% | 14.28% | 11.58% | 52.82% |
| Average Basic Shares Outstanding | -3.13% | -1.79% | 1.58% | -4.47% | -4.89% |
| Average Diluted Shares Outstanding | -2.87% | -2.27% | 1.68% | -2.21% | -2.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |